{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T17:00:27Z","timestamp":1791824427225,"version":"4.3.4"},"reference-count":22,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2011,3,1]],"date-time":"2011-03-01T00:00:00Z","timestamp":1298937600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2011,3]]},"DOI":"10.1124\/dmd.110.036327","type":"journal-article","created":{"date-parts":[[2010,12,10]],"date-time":"2010-12-10T03:34:28Z","timestamp":1291952068000},"page":"394-401","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["CYP3A-Mediated Generation of Aldehyde and Hydrazine in Atazanavir Metabolism"],"prefix":"10.1016","volume":"39","author":[{"given":"Feng","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laiyou","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.110.036327_bib1","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1021\/tx060062o","article-title":"Future of toxicology-metabolic activation and drug design: challenges and opportunities in chemical toxicology","volume":"19","author":"Baillie","year":"2006","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.110.036327_bib2","doi-asserted-by":"crossref","first-page":"1732","DOI":"10.1592\/phco.24.17.1732.52347","article-title":"Atazanavir for the treatment of human immunodeficiency virus infection","volume":"24","author":"Busti","year":"2004","journal-title":"Pharmacotherapy"},{"key":"10.1124\/dmd.110.036327_bib3","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1124\/jpet.106.105213","article-title":"Urinary metabolite profiling reveals CYP1A2-mediated metabolism of NSC686288 (aminoflavone)","volume":"318","author":"Chen","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.110.036327_bib4","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.2165\/00003495-200969080-00009","article-title":"Atazanavir: a review of its use in the management of HIV-1 infection","volume":"69","author":"Croom","year":"2009","journal-title":"Drugs"},{"key":"10.1124\/dmd.110.036327_bib5","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0009-2797(02)00057-1","article-title":"Mechanisms of idiosyncratic drug reactions: the case of felbamate","volume":"142","author":"Dieckhaus","year":"2002","journal-title":"Chem Biol Interact"},{"key":"10.1124\/dmd.110.036327_bib6","doi-asserted-by":"crossref","first-page":"1610","DOI":"10.1097\/01.aids.0000131369.90575.9e","article-title":"Acute hepatic cytolysis in an HIV-infected patient taking atazanavir","volume":"18","author":"Eholi\u00e9","year":"2004","journal-title":"AIDS"},{"key":"10.1124\/dmd.110.036327_bib7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1021\/tx034170b","article-title":"Drug-protein adducts: an industry perspective on minimizing the potential for drug bioactivation in drug discovery and development","volume":"17","author":"Evans","year":"2004","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.110.036327_bib8","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.2165\/00003495-200363160-00003","article-title":"Atazanavir","volume":"63","author":"Goldsmith","year":"2003","journal-title":"Drugs"},{"key":"10.1124\/dmd.110.036327_bib9","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1021\/tx600260a","article-title":"Applying mechanisms of chemical toxicity to predict drug safety","volume":"20","author":"Guengerich","year":"2007","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.110.036327_bib10","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1097\/QAI.0b013e318189a7df","article-title":"Hepatotoxicity and gastrointestinal intolerance when healthy volunteers taking rifampin add twice-daily atazanavir and ritonavir","volume":"50","author":"Haas","year":"2009","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1124\/dmd.110.036327_bib11","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1086\/420932","article-title":"Atazanavir: new option for treatment of HIV infection","volume":"38","author":"Havlir","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1124\/dmd.110.036327_bib12","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1021\/tx600362h","article-title":"Covalent modification of microsomal lipids by thiobenzamide metabolites in vivo","volume":"20","author":"Ji","year":"2007","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.110.036327_bib13","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1124\/dmd.109.030817","article-title":"Metabolism-mediated drug interactions associated with ritonavir-boosted tipranavir in mice","volume":"38","author":"Li","year":"2010","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.110.036327_bib14","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1021\/tx000231j","article-title":"Metabonomic investigations into hydrazine toxicity in the rat","volume":"14","author":"Nicholls","year":"2001","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.110.036327_bib15","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1080\/10408440591002183","article-title":"Aldehyde sources, metabolism, molecular toxicity mechanisms, and possible effects on human health","volume":"35","author":"O'Brien","year":"2005","journal-title":"Crit Rev Toxicol"},{"key":"10.1124\/dmd.110.036327_bib16","first-page":"99","article-title":"Role of atazanavir in the treatment of HIV infection","volume":"5","author":"Rivas","year":"2009","journal-title":"Ther Clin Risk Manag"},{"key":"10.1124\/dmd.110.036327_bib17","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3109\/03602539208996289","article-title":"Acyl glucuronides revisited: is the glucuronidation process a toxification as well as a detoxification mechanism?","volume":"24","author":"Spahn-Langguth","year":"1992","journal-title":"Drug Metab Rev"},{"issue":"Suppl 2","key":"10.1124\/dmd.110.036327_bib18","doi-asserted-by":"crossref","first-page":"S90","DOI":"10.1086\/381444","article-title":"Drug-induced liver injury associated with antiretroviral therapy that includes HIV-1 protease inhibitors","volume":"38","author":"Sulkowski","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1124\/dmd.110.036327_bib19","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.2165\/00003495-200565160-00010","article-title":"Atazanavir: a review of its use in the management of HIV infection","volume":"65","author":"Swainston Harrison","year":"2005","journal-title":"Drugs"},{"key":"10.1124\/dmd.110.036327_bib20","doi-asserted-by":"crossref","first-page":"225","DOI":"10.3109\/03602530903401658","article-title":"Metabolic bioactivation and drug-related adverse effects: current status and future directions from a pharmaceutical research perspective","volume":"42","author":"Tang","year":"2010","journal-title":"Drug Metab Rev"},{"key":"10.1124\/dmd.110.036327_bib21","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1124\/dmd.109.028258","article-title":"Identification and profiling of circulating metabolites of atazanavir, a HIV protease inhibitor","volume":"37","author":"ter Heine","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.110.036327_bib22","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1007\/BF01974343","article-title":"Investigations into the effects of various hepatotoxic compounds on urinary and liver taurine levels in rats","volume":"67","author":"Waterfield","year":"1993","journal-title":"Arch Toxicol"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624057052?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624057052?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.110.036327","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T18:39:28Z","timestamp":1739903968000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624057052"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,3]]},"references-count":22,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,3]]}},"alternative-id":["S0090955624057052"],"URL":"https:\/\/doi.org\/10.1124\/dmd.110.036327","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2011,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CYP3A-Mediated Generation of Aldehyde and Hydrazine in Atazanavir Metabolism","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.110.036327","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2011 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}